ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Marker Therapeutics Inc

Marker Therapeutics Inc (MRKR)

1.54
-0.04
( -2.53% )
Updated: 06:26:40

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.54
Bid
1.48
Offer
1.51
Volume
12,823
1.4801 Day's Range 1.62
1.48 52 Week Range 5.99
Market Cap
Previous Close
1.58
Open
1.56
Last Trade
1
@
1.495
Last Trade Time
06:26:12
Financial Volume
US$ 19,805
VWAP
1.5445
Average Volume (3m)
86,612
Shares Outstanding
8,923,490
Dividend Yield
-
PE Ratio
-1.68
Earnings Per Share (EPS)
-0.92
Revenue
3.31M
Net Profit
-8.24M

About Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more

Sector
Pharmaceutical Preparations
Industry
Business Services, Nec
Headquarters
Wilmington, Delaware, USA
Founded
2006
Marker Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRKR. The last closing price for Marker Therapeutics was US$1.58. Over the last year, Marker Therapeutics shares have traded in a share price range of US$ 1.48 to US$ 5.99.

Marker Therapeutics currently has 8,923,490 shares in issue. The market capitalisation of Marker Therapeutics is US$14.10 million. Marker Therapeutics has a price to earnings ratio (PE ratio) of -1.68.

MRKR Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-11.49425287361.741.741.48675661.57664975CS
4-0.4-20.6185567011.942.16751.48884181.75359702CS
12-2.1-57.69230769233.645.951.48866122.96106122CS
26-2.12-57.92349726783.665.951.48572793.10386077CS
52-2.32-60.1036269433.865.991.48394593.45159916CS
156-2.25-59.36675461743.799.67990.67063461283.9606175CS
260-25.16-94.232209737826.737.70.670659696315.60051629CS

MRKR - Frequently Asked Questions (FAQ)

What is the current Marker Therapeutics share price?
The current share price of Marker Therapeutics is US$ 1.54
How many Marker Therapeutics shares are in issue?
Marker Therapeutics has 8,923,490 shares in issue
What is the market cap of Marker Therapeutics?
The market capitalisation of Marker Therapeutics is USD 14.1M
What is the 1 year trading range for Marker Therapeutics share price?
Marker Therapeutics has traded in the range of US$ 1.48 to US$ 5.99 during the past year
What is the PE ratio of Marker Therapeutics?
The price to earnings ratio of Marker Therapeutics is -1.68
What is the cash to sales ratio of Marker Therapeutics?
The cash to sales ratio of Marker Therapeutics is 4.18
What is the reporting currency for Marker Therapeutics?
Marker Therapeutics reports financial results in USD
What is the latest annual turnover for Marker Therapeutics?
The latest annual turnover of Marker Therapeutics is USD 3.31M
What is the latest annual profit for Marker Therapeutics?
The latest annual profit of Marker Therapeutics is USD -8.24M
What is the registered address of Marker Therapeutics?
The registered address for Marker Therapeutics is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Marker Therapeutics website address?
The website address for Marker Therapeutics is www.markertherapeutics.com
Which industry sector does Marker Therapeutics operate in?
Marker Therapeutics operates in the BUSINESS SERVICES, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ONVOOrganovo Holdings Inc
US$ 1.2184
(230.19%)
344.29M
WAFUWah Fu Education Group Ltd
US$ 3.079
(72.01%)
115.84M
RETOReTo Eco Solutions Inc
US$ 1.01
(71.19%)
64.12M
SLXNSilexion Therapeutics Corporation
US$ 1.09
(45.33%)
84.22M
BREABrera Holdings PLC
US$ 0.905001
(43.36%)
73.1M
YYAIConnexa Sports Technologies Inc
US$ 0.7305
(-42.48%)
5.12M
RNAZTransCode Therapeutics Inc
US$ 3.90
(-42.48%)
499.75k
CLNEClean Energy Fuels Corp
US$ 1.835
(-32.29%)
9.12M
ACONAclarion Inc
US$ 3.1996
(-31.34%)
317.62k
SXTCChina SXT Pharmaceuticals Inc
US$ 4.65
(-30.80%)
1M
ONVOOrganovo Holdings Inc
US$ 1.2184
(230.19%)
339.24M
NVDANVIDIA Corporation
US$ 127.355
(-2.25%)
194.33M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.975
(-19.36%)
137.52M
WAFUWah Fu Education Group Ltd
US$ 3.079
(72.01%)
115.33M
PLTRPalantir Technologies Inc
US$ 87.3297
(-3.69%)
106.35M

MRKR Discussion

View Posts
bar1080 bar1080 8 minutes ago
Well that's a partial answer to a question I've had for decades: Who buys obvious penny stock crap like this. "It’s still a mystery to me what MRKR actual goal was"
👍️0
KeithamdMIC KeithamdMIC 2 hours ago
Your right Phantom we all didn’t dig deep enough to figure out the actual science of this treatment. I dove in because of the so called patents that they acquired on the treatment which obviously didn’t mean anything. I take full responsibility for falling for a bio tech stock with false promises. It’s still a mystery to me what MRKR actual goal was. I thought it was an over the counter’therapy for different cancer related issues. I hadn’t looked at the share price in a long time so I willed myself to look. Not surprised in the least where it’s fallen to.
👍️0
microcapbiotech microcapbiotech 3 hours ago
GREAT NEWS: Conference Call today. We may get an update on the two patients that they first dosed two years ago.
OH HAPPY DAY, wouldn't that be Special.
👍️0
KIPK KIPK 4 hours ago
LOL2020 - The only RS is the one that will be happening to you!!

KARMIC Agenda.....
👍️ 1
learningcurve2020 learningcurve2020 4 hours ago
Maybe we’ll find they added a patient to the trial. 🙄…

Professor Vera, sell this company!!!
👍️ 1
ShadowHaven59 ShadowHaven59 7 hours ago
Any chance we get new information at the conference today?
👍️ 1
microcapbiotech microcapbiotech 4 days ago
My only problem is that NEA ain't as old as me, so after my 25+ years in TPIV/MRKR they can afford to have more patience that me, mine has been running thin for these last few years.
👍️ 1
GoIrish1776 GoIrish1776 4 days ago
NEA is a "true" venture firm with serious Silicon Valley roots. This is what they do. This company just happens to be public. They support their deals if there is an argument to do so.

I assume Baker Bros. is a hedge fund at heart, wants losers off their books if need be, etc. That said, I remember thinking, "They are being disciplined," when it happened. It was the smart move.

As a side note, it looks like the PI for OTS in AML is using lymphodepletion. If I read that correctly, that seems new (I think) and is consistent with a company mention that they did seem to see the benefit of that. Prior, they consistently said they didn't think it was necessary. (I'm running fast, so anyone should correct me if I have the facts wrong.)
👍️ 1
microcapbiotech microcapbiotech 4 days ago
Holy S--T, I was not aware of that. That kind of sucks.
I think for this post I am not going to click on the green bull emoji.
👍️0
Phantom Lord Phantom Lord 5 days ago
Baker brother bought in at the initial merger. Ended up selling their shares and their warrants expired worthless. Unlike NEA I would assume Baker brothers learned their lesson.
👍️ 3
microcapbiotech microcapbiotech 5 days ago
Yep, being that I never heard of Alyeska, Blue Owl, or Hudson Bay, it doesn't really inspire too much added confidence. Now if I see Baker Brothers come in with 5 or 10 million, I would take that as a good sign. I follow them just to see what their new investments are every quarter, they seem to do really well, I followed them into SMMT (SMMT worked well in China beating Keytruda, we will see about what happens in the US).
👍️ 1
Phantom Lord Phantom Lord 5 days ago
No real opinion. They made the same mistake all of us did putting money here too early. Their just able to pump more money into it in hopes of making something back. Don't care about the new investors much. They won't have a hand in if the company actually gets their shit together.
👍️ 2
microcapbiotech microcapbiotech 5 days ago
Phantom, Any opinion on NEA increasing their shares by 52% to 2.8 million dollars and Alyeska, Blue Owl, and Hudson Bay coming in with a combined 3 million (more than NEA currently has)?
Thanks
👍️0
GoIrish1776 GoIrish1776 5 days ago
Looks like they are pivoting to include an HMA for AML...?
https://clinicaltrials.gov/study/NCT06552416
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-mt-401-non-clinical-data-aml-cells

I believe the Baylor data for lymphoma was also about 40% also. There is a research report "out there" articulating it, but I don't have time to dig it up now. If they went head to head with CAR-T and were equivalent, this would be a blockbuster because 40% is of people ineligible or who failed CAR-T. However, that test is very unlikely to happen.
👍️ 2
Phantom Lord Phantom Lord 6 days ago
I do not recall off the top of my head what the 401 results were but I don't believe the response rates were better than the 601 results. That being said we can't really compare the two because they are targeting two different types of cancers.
👍️ 2
Flyingj Flyingj 6 days ago
Phantom, do you recall the results from the the 401 Lymphoma trial. So far the 601 trial has a 44% complete response rate and a 77% objective response rate. I'm asking if the 601 formula appears to be any better than the 401 formula?
👍️ 2
ShadowHaven59 ShadowHaven59 1 week ago
Any guesses?? I’m going to take this as a positive.
👍️ 1
KIPK KIPK 1 week ago
LC2020 - And you are so sure of YOU, that you give Your own post a thumbsy up...

LOL - KARMA!!!
👍️ 2
microcapbiotech microcapbiotech 1 week ago
Despite the price that has been going down. This just reported, a tiny bit interesting, NEA increases shares by 52%,
plus 3 new large buyers, which means ????
Owner Name Date Shares Held Change (Shares) Change (%) Value (In 1,000s)
Nea Management Company, Llc 12/31/2024 1,625,678 554,250 51.73% $2,796
Alyeska Investment Group, L.P. 12/31/2024 915,591 915,591 New $1,575
Blue Owl Capital Holdings Lp 12/31/2024 554,250 554,250 New $953
Hudson Bay Capital Management Lp 12/31/2024 331,670 331,670 New $570
👍️ 1
learningcurve2020 learningcurve2020 2 weeks ago
Funny the mod chooses to leave your post up? Nearly everything I’ve predicted has come true, in case you didn’t notice. So, destroying by facts, I guess. But at least you rightfully got kicked off the NWBO board.
👍️ 1
KIPK KIPK 2 weeks ago
LC2020. Your over 10 years history of trying to help destroy NWBO is well documented with or without adding that peace to your recent post!!.. ........>If True> ............. KARMA watching...


748884
of 748884
…I should’ve included “If true
👍️ 2 🪠 1
microcapbiotech microcapbiotech 2 weeks ago
Well, you, me and everybody else may just have to give it another year ...........
........... or 5 ........
........... or 10.
👍️ 1
microcapbiotech microcapbiotech 2 weeks ago
It's close but I'll vote Peter.
👍️0
ShadowHaven59 ShadowHaven59 2 weeks ago
Me!!! for buying this stock😥 I can’t believe I’ve given a hope,
👍️ 1
ah86 ah86 2 weeks ago
Who is worse, Peter Huang or Juan Vera?
👍️ 2
bar1080 bar1080 2 weeks ago
Terrible news for our local biomed shills. notice
MRKR's fall.
👍️0
bar1080 bar1080 2 weeks ago
Here come DEEP Trump Cuts to biomed research. Front page news everywhere. Way overdue.
👍️0
KIPK KIPK 3 weeks ago
LC2020 - Irrelevant posts as usual for a buck or two$. SAD...
👍️ 2
learningcurve2020 learningcurve2020 3 weeks ago
Looks like same bias here as on NWBO. 
👍️0
KIPK KIPK 3 weeks ago
LC2020 -
This comment below you posted is very RICH (lol) coming from someone who posts antagonistically for a living... DELUTIONAL..

"""If you folks are ever ready to have a big boy conversation on the pros and cons of such, I’ll be glad to provide my opinion.:"::

LOL
👍️ 1
learningcurve2020 learningcurve2020 3 weeks ago
…They call it “Research for researches sake along with great salaries provided by poor unknowing retail for the benefit of big Pharma”.
👍️0
learningcurve2020 learningcurve2020 3 weeks ago
Here we go again! Raise millions then drive the company into the ground then reverse merge / reverse split, and then do it all over again. Management gets rich while shareholders go broke. They’ve already done the deal so…

Noticed it said that no other matters were up for consideration. So much for shareholder activism. Sigh.
👙 1
jobynimble jobynimble 3 weeks ago
Proxy filings…

https://www.sec.gov/Archives/edgar/data/1094038/000110465925009098/tm253006-2_def14a.htm

https://www.sec.gov/Archives/edgar/data/1094038/000110465925009098/tm253006-2_def14a.htm

Marker Therapeutics
2450 Holcombe Blvd, Suite BCM-A, MS: BCM251
Houston, TX 77021

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

To Be Held On March 21, 2025

Dear Stockholder:
You are cordially invited to attend the Special Meeting of Stockholders of Marker Therapeutics, Inc., a Delaware corporation (the “Company”). The meeting will be held on Friday, March 21, 2025 at 9:00 a.m. Central Time and will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. You must register for the virtual meeting via https://web.viewproxy.com/markertherapeutics/2025SM no later than 11:59 p.m. Eastern Time on Thursday, March 20, 2025. The meeting will be held for the following purposes:
1.
To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of the shares issuable upon exercise of (i) Series A Warrants to acquire 5,031,250 shares of Common Stock (the “Private Placement Warrants”) and (ii) Series B Warrants to acquire 3,247,445 shares of Common Stock (the “Pre-Funded Warrants”, and together with the Private Placement Warrants, the “Warrants”).

2.
To conduct any other business properly brought before the meeting.

These items of business are more fully described in the Proxy Statement accompanying this Notice.
The record date for the Special Meeting is January 27, 2025. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.


Click above links for complete filings…
👍️ 3
learningcurve2020 learningcurve2020 3 weeks ago
Hey Vera, SELL THIS COMPANY!
👍️0
KIPK KIPK 3 weeks ago
LC2020. Over 16000 post in over 12 years!! Think DISCOVERY!!!
👍️ 1
CorsairNavigator20 CorsairNavigator20 4 weeks ago
He is a successful business person, woke up (pun intended) and said, do I really want to be ignored. He walked away and will come back to buy us for ten cents on the dollar. The good news, there's none for us.
👍️ 1
Flyingj Flyingj 4 weeks ago
https://scitechdaily.com/scientists-unlock-the-secret-to-supercharged-cancer-fighting-t-cells/
👍️ 1
Buckboard Buckboard 4 weeks ago
I was told it was DEI's fault. Do I win? Thank you.
👍️ 1 😂 2
ShadowHaven59 ShadowHaven59 4 weeks ago
Any guesses out there, on why he resigned and what’s going to happen next? The correct guess wins a prize.lol
👍️ 1
learningcurve2020 learningcurve2020 4 weeks ago
It’s important to keep this guy’s name at the top just for accountability’s sake. Don’t let the link just disappear.

Dr. Huseynov:

https://www.moomoo.com/news/post/44817152/ladenburg-thalmann-maintains-marker-therapeutics-mrkrus-with-buy-rating-raises?level=2&data_ticket=1737645360288002

https://stockanalysis.com/analysts/aydin-huseynov/

https://www.benchmarkcompany.com/the-benchmark-company-expands-its-biotechnology-focus-with-the-addition-of-dr-aydin-huseynov-and-dr-okechukwu-linton/
👍️0
ShadowHaven59 ShadowHaven59 4 weeks ago
Thank you 👍
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
Hopefully they sell the tech long before that because management were a total failure for shareholders, and now it feels like their remnants turned into a One man show.
👍️0
Phantom Lord Phantom Lord 4 weeks ago
That would have been in reference to the PII AML trial which was a "potentially pivotal" trial. Pivotal means that if the trial concludes with data above a certain threshold then a PIII is not required. That AML trial has been terminated as they pivot to focussing on their OTS therapy in AML. If that trial, or the PII in lymphoma if they can ever get the damn PI completed, are designated as pivotal then they may be able to avoid a PIII trial but until we have more data and information on the next steps it's not worth thinking about, IMO.
👍️ 2
learningcurve2020 learningcurve2020 4 weeks ago
Good for governance. 👏🏼👏🏼 That’s one less conflict to worry about.

>>On January 24, 2025, Mr. John Wilson resigned from the Board of Directors of Marker Therapeutics, Inc. (the “Company”).
👍️0
Buckboard Buckboard 4 weeks ago
Thanks
👍️0
ah86 ah86 4 weeks ago
Good move from Wolfie.
Marker's shareholders built the facility and he got a good deal. No more utility from this sinking abomination, so, bye bye
👍️0
jobynimble jobynimble 4 weeks ago
It’s in an 8-K filing that was alerted by the icon next to the symbol for this board’s header…

MRKR Marker Therapeutics Inc
👍️ 2
ShadowHaven59 ShadowHaven59 4 weeks ago
How did you receive notice? wouldn’t that have to be disclosed to the public? Also wouldn’t that be a bad sign?
👍️0
CorsairNavigator20 CorsairNavigator20 4 weeks ago
I received notice that Wilson from the board of directors resigned. He is the one that bought the manufacturing rights. Will he buy the rest of the company? Time to get the conspiracy theories going. 😁
👍️0
ShadowHaven59 ShadowHaven59 4 weeks ago
Phantom Lord, I went back on stock twits and started reading your old posts on there. I read in your older post. There was a possibility of them having the ability to skip a phase 3 trial. Is that possibility no longer available in your opinion? I apologize if this has been answered and I’m not trying to rehash old posts, I am just trying to. look for a silver lining. A light at the end of the tunnel. Lol thank you
👍️ 1